SRX Global Inc.
No enriched coverage for $SRXH in the last 7 days.
No SEC Form 4 filings for $SRXH in the last 30 days.
See all $SRXH insider activity →SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte
Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
SRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.
Recent SRXH coverage spans corporate actions, earnings and financial news.
Positive cash position and dividend may support the stock, but modest earnings and ongoing losses limit upside.
Stake acquisition and engagement intent can support sentiment, but without disclosed size or terms it is less actionable than a formal deal.
Stake acquisition creates a near-term sentiment catalyst for SRXH, but the article provides no deal size or financial terms.
The 8-K confirms incremental equity-linked financing via unregistered sales, which can pressure valuation via dilution risk and improve near-term liquidity.
The waiver removes investor friction around capital return and authorizes a defined buyback capacity, which can shift near-term valuation and liquidity expectations.
alphai scores every news story that mentions SRXH with an AI model for sentiment and relevance, and aggregates insider trades from SRX Global Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte
2 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readSRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.
3 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001471727 0001471727 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
2 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001471727 0001471727 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
3 min readSRX Global Inc. (NYSE American: SRXH) reported paper-traded EMJX crypto-treasury returns of about 24.8% (time-weighted) from Feb. 11 to July 10, 2026, versus Bitcoin at -4.2% over the same period. The EMJX regime model shifts among Bull, Mixed, and Stress and will start trading with real capital after an acquisition. Management plans a July 14 fireside chat.
3 min readSRX Global, Inc. (NYSE American: SRXH) said CEO Kent Cunningham and President Eric Jackson will host a virtual fireside chat on July 14, 2026 at 10:30 a.m. ET to discuss developments and the completed EMJX acquisition. In a shareholder letter, the company cited $55 million+ cash and short-term investments, no debt, net asset value about $3.07 per share, plus a repurchase plan for up to 10 million shares and a dividend totaling about $1 million.
4 min readSRX Global Inc. (NYSE American: SRXH) said its board authorized a share repurchase plan to buy up to 10 million shares or as much as 50% of shares outstanding. The company allocated up to $20 million for repurchases through July 9, 2027, funded by cash on hand, with timing dependent on market and other factors.
3 min readSRX Global Inc. (SRXH) reported preliminary balance sheet results after acquiring EMJX and completing a 1-for-60 reverse stock split on July 6, 2026. As of June 30, 2026, it estimated net asset value at about $60 million, or $3.07 per share, with about $40 million cash, over $15 million in short-term investments, and no debt. SRXH shares outstanding were about 19.5 million post-split.
3 min readSRX Global Inc. (NYSE American: SRXH) reported preliminary balance sheet metrics after its EMJX acquisition and a July 6, 2026 reverse stock split. As of June 30, 2026, it estimated NAV of about $60 million, or $3.07 per share, with roughly $40 million cash, over $15 million short-term investments, and no debt. Shares outstanding were about 19.52 million.
3 min read
